Search
Atractylodes japonica root oil
go.drugbank.com/drugs/DB11270ApprovedWithdrawnIt is present in some cosmetic products such as whitening creams as an active ingredient and lubricant for skin irritation. … Atractylodes japonica root oil is obtained from the roots of Atractylodes japonica, which is a herb native to eastern Asia.
Vayarin
go.drugbank.com/drugs/DB09328ApprovedA slow response time of 12 weeks is an impediment to successful management of ADHD as only 41.6% of subjects prescribed Vayarin remained compliant for the duration of the study. … Vayarin is a novel therapy for ADHD that appears to be effective in several studies [L1501, L1502, L1503].
Galocitabine
go.drugbank.com/drugs/DB21373ExperimentalGalocitabine has a monoisotopic molecular weight of 439.14 Da. … Galocitabine is a small molecule drug.
Ancitabine
go.drugbank.com/drugs/DB20595ExperimentalAncitabine has a monoisotopic molecular weight of 225.07 Da. … Ancitabine is a small molecule drug.
Alpibectir
go.drugbank.com/drugs/DB21561InvestigationalAlpibectir has a monoisotopic molecular weight of 332.1 Da. … Alpibectir is a small molecule drug.
Ceperognastat
go.drugbank.com/drugs/DB21591InvestigationalCeperognastat has a monoisotopic molecular weight of 383.14 Da. … Ceperognastat is a small molecule drug.
Ranosidenib
go.drugbank.com/drugs/DB21727InvestigationalRanosidenib has a monoisotopic molecular weight of 453.12 Da. … Ranosidenib is a small molecule drug. Ranosidenib is under investigation in clinical trial NCT06387069 (A Study to Evaluate HMPL-306 in Patients With IDH1- and IDH2-mutated Acute Myeloid Leukemia).
Utatrectinib
go.drugbank.com/drugs/DB21295InvestigationalUtatrectinib has a monoisotopic molecular weight of 382.17 Da. … Utatrectinib is a small molecule drug. The usage of the INN stem '-trectinib' in the name indicates that Utatrectinib is a tropomyosin receptor kinase (TRK) inhibitor.
Aleglitazar
go.drugbank.com/drugs/DB08915InvestigationalAleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO. … Aleglitazar is an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPARα and PPARγ receptor subtypes.
Votucalis
go.drugbank.com/drugs/DB05032InvestigationalIt is a topically delivered small protein that acts as an anti-inflammatory agent.